{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:53:19Z","timestamp":1790920399040,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009733.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000}}],"reference-count":99,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009733.pub4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:24:39Z","timestamp":1770809079000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders"],"prefix":"10.1002","volume":"2026","author":[{"given":"Rita","family":"Champaneria","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Nuffield Department of Clinical Laboratory Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"},{"name":"Radcliffe Department of Medicine; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Geneen","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Nuffield Department of Clinical Laboratory Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J","family":"Brunskill","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Nuffield Department of Clinical Laboratory Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Dor\u00e9e","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Nuffield Department of Clinical Laboratory Sciences; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Stanworth","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"},{"name":"Radcliffe Department of Medicine; University of Oxford; Oxford UK"},{"name":"Department of Haematology; Oxford University Hospitals NHS Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael JR","family":"Desborough","sequence":"additional","affiliation":[{"name":"Systematic Review Initiative; NHS Blood and Transplant; Oxford UK"},{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"},{"name":"Radcliffe Department of Medicine; University of Oxford; Oxford UK"},{"name":"Department of Haematology; Oxford University Hospitals NHS Trust; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"British Journal of Haematology"},{"issue":"19","key":"10.1002\/14651858.CD009733.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0003|cit3","volume-title":"2023 Annual SHOT Report","author":"Narayan","year":"2024"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/j.seminhematol.2019.10.001","article-title":"Platelet transfusion: alloimmunization and refractoriness","volume":"57","author":"Prodger","year":"2020","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0005|cit5","unstructured":"NHS Blood and Transplant Blood Components Cost per Item 2024\/25 https:\/\/nhsbtde.blob.core.windows.net\/umbraco-assets-corp\/34945\/price_list_cost-per-item_2024-25.pdf"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1537-2995.2007.01090.x","article-title":"Evaluation of platelet transfusion triggers in a tertiary-care hospital","volume":"47","author":"Cameron","year":"2007","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1537-2995.2007.01089.x","article-title":"Platelet utilisation and the transfusion trigger: a prospective analysis","volume":"72","author":"Greeno","year":"2007","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0008|cit8","first-page":"17","article-title":"An audit of the use and wastage in the North West of England and North Wales - where have all the platelets gone?","volume":"34","author":"Pendry","year":"2011","journal-title":"Blood and Transfusion Matters"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Metcalf RA Nahirniak S Guyatt G Bathla A White SK Al-Riyami AZ Platelet transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines JAMA 2025 334 7 606 17","DOI":"10.1001\/jama.2025.7529"},{"issue":"10","key":"10.1002\/14651858.CD009733.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(20)30186-1","article-title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","volume":"7","author":"Stanworth","year":"2022","journal-title":"Lancet Haematology"},{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/bjh.14338","article-title":"Alternatives to allogeneic platelet transfusion","volume":"175","author":"Desborough","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD009733.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-2007-996127","article-title":"Enzyme-controlling medicines: introduction","volume":"23","author":"Okamoto","year":"1997","journal-title":"Seminars in Thrombosis and Hemostasis"},{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0887-7963(98)80061-8","article-title":"Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature","volume":"12","author":"Faught","year":"1998","journal-title":"Transfusion Medicine Reviews"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"e3054","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis","volume":"344","author":"Ker","year":"2012","journal-title":"BMJ"},{"issue":"9734","key":"10.1002\/14651858.CD009733.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"Shakur","year":"2010","journal-title":"Lancet"},{"issue":"10241","key":"10.1002\/14651858.CD009733.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"HALT-IT Trial Collaborators","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.blre.2018.06.002","article-title":"Venous thromboembolism in hematologic malignancies","volume":"33","author":"Kekre","year":"2019","journal-title":"Blood Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0018|cit18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733","article-title":"Anti-fibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders","author":"Wardrop","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0019|cit19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733.pub3","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders","author":"Estcourt","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD009733.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood.2022016308","article-title":"Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial","volume":"140","author":"Gernsheimer","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD009733.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/bloodadvances.2022008255","article-title":"Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia","volume":"7","author":"Ilich","year":"2023","journal-title":"Blood Advances"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009733.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2023-186654","article-title":"Bleeding risk factors in thrombocytopenic patients with hematologic malignancies","volume":"142","author":"Poston","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009733.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2021-146898","article-title":"Absence of hyperactivation of fibrinolysis explains the lack of hemostatic efficacy of prophylactic tranexamic acid (TXA) in hypoproliferative thrombocytopenia","volume":"138","author":"Ilich","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD009733.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/trf.18028","article-title":"Analysis of bleeding outcomes in patients with hypoproliferative thrombocytopenia in the A-TREAT clinical trial","volume":"64","author":"Poston","year":"2024","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"102358","DOI":"10.1016\/j.rpth.2024.102358","article-title":"Fewer severe infections with tranexamic acid in patients with hematologic malignancies","volume":"8","author":"Poston","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009733.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-138920","article-title":"Effects of tranexamic acid prophylaxis on bleeding outcomes in hematologic malignancy: the a-TREAT trial","volume":"136","author":"Gernsheimer","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0027|cit27","unstructured":"Brown SP May SJ Gernsheimer TB (University of Washington School of Medicine) Personal communication Email to: R Champaneria (Systematic Review Initiative, NHSBT, Oxford, UK)."},{"key":"10.1002\/14651858.CD009733.pub4-BIB0028|cit28","unstructured":"American trial using tranexamic acid in thrombocytopenia (A-TREAT) https:\/\/clinicaltrials.gov\/study\/NCT02578901"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0029|cit29","first-page":"e14\u201322","article-title":"Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial","volume":"12","author":"TREATT Trial Investigators","year":"2025","journal-title":"Lancet Haematology"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0030|cit30","unstructured":"Parsons J Hudson C Personal communication Email to: R Champaneria (Systematic Review Initiative, NHSBT, Oxford, UK)."},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009733.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2023-180720","article-title":"Tranexamic acid to prevent bleeding in patients with hematologic malignancies and severe thrombocytopenia (TREATT trial): a randomized placebo-controlled trial","volume":"142","author":"Estcourt","year":"2023","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0032|cit32","unstructured":"Estcourt LJ Personal communication Email to: R Champaneria (Systematic Review Initiative, NHSBT, Oxford, UK)"},{"issue":"1","key":"10.1002\/14651858.CD009733.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s13063-019-3663-2","article-title":"The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial","volume":"20","author":"Estcourt","year":"2019","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0034|cit34","unstructured":"A double-blind, randomised controlled trial evaluating the safety and efficacy of antifibrinolytics (tranexamic acid) in patients with haematological malignancies with severe thrombocytopenia https:\/\/clinicaltrials.gov\/study\/NCT03136445"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"A double blind, randomised controlled TRial EvaluAting the safety and efficacy of Tranexamic acid in patients with haematological malignancies with severe Thrombocytopenia (TREATT) https:\/\/doi.org\/10.1186\/ISRCTN73545489","DOI":"10.1186\/ISRCTN73545489"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0037|cit37","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews Cochrane: London,"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0038|cit38","first-page":"202a","article-title":"Antifibrinolytic therapy for bleeding control during remission induction for acute leukemia","volume":"62","author":"Gallardo","year":"1983","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0039|cit39","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Chapter 4: Searching for and selecting studies [last updated September 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0040|cit40","unstructured":"Li T Higgins JP Deeks JJ Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"7","key":"10.1002\/14651858.CD009733.pub4-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009733.pub2","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders","author":"Wardrop","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0042|cit42","unstructured":"Higgins JP Savovic J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"4","key":"10.1002\/14651858.CD009733.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1537-2995.1991.31491213301.x","article-title":"Lack of efficacy of tranexamic acid in thrombocytopenic bleeding","volume":"31","author":"Fricke","year":"1991","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0045|cit45","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized controlled trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0046|cit46","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Addressing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD009733.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-134794","article-title":"A pilot study to evaluate the feasibility of anti-fibrinolytic agents in reducing hemorrhagic complications in pediatric patients with thrombocytopenia","volume":"136","author":"McCormick","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0048|cit48","unstructured":"NHSBT Personal communication Email to: McCormick M."},{"key":"10.1002\/14651858.CD009733.pub4-BIB0049|cit49","unstructured":"A pediatric trial using tranexamic acid in thrombocytopenia https:\/\/clinicaltrials.gov\/study\/NCT03806556"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0050|cit50","unstructured":"Prevention of bleeding in hematological malignancies with antifibrinolytic (epsilon aminocaproic acid) (PROBLEMA) https:\/\/clinicaltrials.gov\/study\/NCT02074436"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0051|cit51","unstructured":"NHS Blood and Transplant Personal communication Email to: Antun AG."},{"key":"10.1002\/14651858.CD009733.pub4-BIB0052|cit52","unstructured":"Evolution of thromboelastography during tranexamic acid treatment (TTRAP-bleeding) https:\/\/clinicaltrials.gov\/study\/NCT03801122"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0053|cit53","unstructured":"Chalayer E (Centre Hospitalier Universitaire de Saint-\u00c9tienne) [personal communication]. Email to: R Champaneria (Systematic Review Initiative, NHSBT, Oxford, UK) Email"},{"issue":"10","key":"10.1002\/14651858.CD009733.pub4-BIB0054|cit54","first-page":"e013483","article-title":"Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study","volume":"6","author":"Allan","year":"2016","journal-title":"British Medical Journal Open"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0055|cit55","unstructured":"Tinmouth A Fergusson D [personal communication]. Email to: SJ Brunskill (Systematic Review Initiative, NHSBT, Oxford, UK) Email"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0056|cit56","unstructured":"Platelet transfusions in hematopoietic stem cell transplantation - the PATH phase III trial https:\/\/clinicaltrials.gov\/study\/NCT04448184?viewType=Table&term=NCT04448184&rank=1"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0057|cit57","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2025"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0058|cit58","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Chapter 14: Completing 'Summary of findings' tables and grading the certainty of evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/training.cochrane.org\/handbook\/archive\/v6.4"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0059|cit59","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"issue":"8655","key":"10.1002\/14651858.CD009733.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"334","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/10428199509059668","article-title":"A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia","volume":"19","author":"Shpilberg","year":"1995","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0062|cit62","first-page":"547a","article-title":"A controlled trial of tranexamic acid (TA) treatment for reduction of bleeding during acute myeloid leukemia (AML) induction and consolidation","volume":"82","author":"Shpilberg","year":"1993","journal-title":"Blood"},{"issue":"(Supplement 1)","key":"10.1002\/14651858.CD009733.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"8489","DOI":"10.1182\/blood-2022-164491","article-title":"Comparison between intermittent bolus versus continuous intravenous infusion of tranexamic acid in hematological disorders with thrombocytopenia (BRAVE TRIAL)- a randomized, OPEN label, single centre study","volume":"140","author":"Byreddy","year":"2022","journal-title":"Blood"},{"issue":"(Supplement 1)","key":"10.1002\/14651858.CD009733.pub4-BIB0064|cit64","article-title":"Comparison between intermittent bolus versus continuous intravenous infusion of tranexamic acid in hematological disorders with thrombocytopenia (BRAVE Trial)","volume":"6","author":"Poojitha","year":"2022","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0065|cit65","unstructured":"Intermittent bolus versus continuous infusion of tranexamic acid in low platelets https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2020\/07\/026319"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0066|cit66","unstructured":"A comparative study of the effect of mouthwashes containing tranexamic acid and nanotrangasemic acid in leukemia patients https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20230104057046N2"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00000542-200302000-00011","article-title":"Antifibrinolytic therapy and perioperative blood loss in cancer patients undergoing major orthopedic surgery","volume":"98","author":"Amar","year":"2003","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0068|cit68","first-page":"P","article-title":"Quality of life (QOL) evaluation in women with menorrhagia and abnormal hemostasis testing participating in a cross-over study of intranasal desmopressin and oral tranexamic acid","volume":"5","author":"Byams","year":"2007","journal-title":"Journal of Thrombosis and Hemostasis"},{"issue":"5","key":"10.1002\/14651858.CD009733.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"637","DOI":"10.15537\/1658-3175.3419","article-title":"The role of antifibrinolytic agents in gynecologic cancer surgery","volume":"27","author":"Celebi","year":"2006","journal-title":"Saudi Medical Journal"},{"issue":"6","key":"10.1002\/14651858.CD009733.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3109\/17453674.2011.623568","article-title":"Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray","volume":"82","author":"McConnell","year":"2011","journal-title":"Acta Orthopaedica"},{"issue":"4","key":"10.1002\/14651858.CD009733.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.knee.2011.06.004","article-title":"Reducing blood loss in primary knee arthroplasty: a prospective randomised controlled trial of tranexamic acid and fibrin spray","volume":"19","author":"McConnell","year":"2012","journal-title":"Knee"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0072|cit72","first-page":"325","article-title":"Tranexamic acid in prevention of oropharyngeal radiomucositis","volume":"69","author":"Mevio","year":"1983","journal-title":"Radiologia Medica"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ijgo.2011.07.015","article-title":"Effects of intravenous tranexamic acid administration on blood loss during and after cesarian delivery","volume":"115","author":"Movafegh","year":"2011","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0074|cit74","unstructured":"Chung M TXA study in major oncologic surgery ClinicalTrials.gov [Accessed August 12th 2015]"},{"issue":"10","key":"10.1002\/14651858.CD009733.pub4-BIB0075|cit75","first-page":"590","article-title":"Clinical study on the efficacy of tranexamic acid in reducing postpartum blood loss: a randomized, comparative, multicenter trial","volume":"36","author":"Yang","year":"2001","journal-title":"Chinese Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S1010-7940(01)01016-8","article-title":"Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study","volume":"20","author":"Bedirhan","year":"2001","journal-title":"European Journal of Cardio-thoracic Surgery"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0077|cit77","first-page":"174","article-title":"Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery","volume":"85","author":"Jeserschek","year":"2003","journal-title":"Journal of Bone and Joint Surgery"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0078|cit78","first-page":"236","article-title":"The effects of intraoperative aprotinin on perioperative haemostasis and fibrinolysis and their effects on blood loss and transfusion requirements in lung surgery","volume":"25","author":"Katzel","year":"1998","journal-title":"Infusionstherapie und Transfusionsmedizin"},{"issue":"21","key":"10.1002\/14651858.CD009733.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/cncr.28253","article-title":"Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies","volume":"119","author":"Antun","year":"2013","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1001\/archinte.1989.00390090039008","article-title":"Control of bleeding in patients with immune and non-immune thrombocytopenia with aminocaproic acid","volume":"149","author":"Bartholomew","year":"1989","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1600-0609.1990.tb00423.x","article-title":"Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions","volume":"45","author":"Ben-Bassat","year":"1990","journal-title":"European Journal of Haematology"},{"issue":"43","key":"10.1002\/14651858.CD009733.pub4-BIB0082|cit82","first-page":"2037","article-title":"Trial of epsilon-amino-caproic acid in patients with a bleeding disorder, in particular thrombocytopenic disorders","volume":"71","author":"Cattan","year":"1963","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0609.1998.tb01046.x","article-title":"Low dose bolus aminocaproic acid: an alternative to platelet transfusion in thrombocytopenia","volume":"60","author":"Chakrabarti","year":"1998","journal-title":"European Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD009733.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0885-3924(96)00202-3","article-title":"Fibrinolytic inhibitors for cancer-associated bleeding problems","volume":"3","author":"Dean","year":"1997","journal-title":"Journal of Pain and Symptom Management"},{"issue":"28","key":"10.1002\/14651858.CD009733.pub4-BIB0085|cit85","first-page":"1368","article-title":"Cyklokapron (tranexamic acid) in the treatment of patients with advanced neoplasms","volume":"98","author":"Fossa","year":"1978","journal-title":"Tidsskrift for Den Norske Laegeforening"},{"issue":"1","key":"10.1002\/14651858.CD009733.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1980.03300270023023","article-title":"Aminocaproic acid: use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia","volume":"243","author":"Gardner","year":"1980","journal-title":"Journal of American Medical Association"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1600-0609.1985.tb02818.x","article-title":"Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients","volume":"35","author":"Garewal","year":"1985","journal-title":"Scandinavian Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD009733.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.21958","article-title":"Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage","volume":"107","author":"Kalmadi","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/bmt.2014.287","article-title":"Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage","volume":"50","author":"Rathi","year":"2015","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0049-3848(10)70013-X","article-title":"Open issues on bleeding and thrombosis in acute promyelocytic leukemia","volume":"125","author":"Sanz","year":"2010","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.7326\/0003-4819-105-6-873","article-title":"Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency","volume":"105","author":"Schwartz","year":"1986","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hon.867","article-title":"Acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients","volume":"26","author":"Wassenaar","year":"2008","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1592\/phco.31.11.1092","article-title":"Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy","volume":"11","author":"Bates","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2011.08922.x","article-title":"The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia","volume":"156","author":"Breen","year":"2011","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2516.2002.00653.x","article-title":"Haemostasis: from bench to bedside","volume":"8","author":"Brown","year":"2002","journal-title":"Haemophilia"},{"key":"10.1002\/14651858.CD009733.pub4-BIB0096|cit96","first-page":"43","volume-title":"IARS Review Course Lectures","author":"Levy","year":"2005"},{"issue":"6","key":"10.1002\/14651858.CD009733.pub4-BIB0097|cit97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008562.pub2","article-title":"Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia","author":"Marti-Carvajal","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD009733.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0049-3848(07)70137-8","article-title":"Bleeding and thrombosis in acute leukemia: what does the future of therapy look like?","volume":"120","author":"Rickles","year":"2007","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD009733.pub4-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/jha2.699","article-title":"Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy","volume":"4","author":"B\u00f8nl\u00f8kke","year":"2023","journal-title":"eJHaem"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:04:01Z","timestamp":1790917441000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009733.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":99,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009733.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}